文献速递淋巴瘤

整合分子分析揭示TP53突变弥漫大B细胞淋巴瘤临床结局的决定因素

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2026-04-29

该研究基于10个队列3091例初治DLBCL患者,结合测序与转录组数据,发现TP53突变淋巴瘤在遗传病变模式、恶性B细胞表达状态和微环境组成上与野生型不同;VAF≥75%提示LOH且预后更差,干扰素信号下调和巨噬细胞含量低与不良结局相关;Phoenix试验再分析显示R-CHOP联合伊布替尼可改善TP53突变患者PFS并消除高VAF的不良影响。

要点

  • TP53突变频率是MYC/BCL2/BCL6双/三打击的6倍,但不良预后风险相似。
  • TP53突变患者中VAF≥75%提示LOH,PFS/OS显著更差。
  • Phoenix试验再分析:R-CHOP加伊布替尼改善TP53突变DLBCL的PFS,不受年龄影响。

核心结论

  • TP53突变DLBCL的不良预后取决于内在特征如VAF,并受共现基因组病变或淋巴瘤细胞内在/微环境表达模式调节。

研究设计与样本

  • 研究纳入10个队列共3091例初治DLBCL患者,均接受一线利妥昔单抗为基础免疫化疗,全部有靶向或全外显子/全基因组测序数据,591例样本进行bulk RNA-seq分析。

主要发现

  • TP53突变DLBCL在遗传病变模式和数量、恶性B细胞表达状态及肿瘤微环境组成上与野生型不同。
  • TP53突变频率是MYC/BCL2/BCL6双/三打击状态的6倍,但赋予相似的不良预后风险。
  • TP53突变患者中VAF≥75%(提示LOH)者PFS/OS显著更差。
  • 不良结局或VAF≥75%的TP53突变样本中可见干扰素信号下调和巨噬细胞含量降低。
  • TP53突变在特定LymphGen亚型(EZB、MCD)、恶性B细胞状态(S1)和生态型(LE4、LE7、LE8)中具有不良预后意义,而在其他分子亚型中结局与野生型相似。

临床怎么用

  • 对TP53突变DLBCL患者应评估VAF,VAF≥75%提示LOH且预后更差,可考虑强化治疗或临床试验。
  • R-CHOP联合伊布替尼可能改善TP53突变DLBCL的PFS,尤其高VAF患者,但需结合Phoenix试验背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Mutations in TP53, detected in over 20% of diffuse large B-cell lymphomas (DLBCLs), are associated with poor prognosis. However, clinical outcomes among patients with TP53-mutant disease vary, with some patients showing treatment responses similar to those with wild-type TP53. This study aims to understand the clinical and molecular determinants underlying poor outcomes in TP53-mutant DLBCL. METHODS: Clinical and molecular data for 3,091 patients were derived from 10 cohorts of patients with newly diagnosed DLBCL treated with frontline rituximab-based immunochemotherapy regimens. Targeted or whole-exome/whole-genome sequencing was available for all patients. Bulk RNA-seq was analyzed for 591 patient samples. The primary outcome measures were progression-free survival (PFS) and overall survival (OS). RESULTS: TP53-mutant DLBCL differed from wild-type disease in pattern and number of genetic lesions, malignant B-cell expression states, and tumor microenvironment composition. TP53 mutations were 6-fold more prevalent than MYC/BCL2/BCL6 double-/triple-hit status, but conferred similar adverse prognostic risk. Among patients with TP53-mutant disease, variant allele frequency (VAF) further stratified risk, with patients featuring VAF ≥ 75% (indicative of loss of heterozygosity) experiencing significantly inferior PFS/OS. Downregulation of interferon signaling and lower macrophage content were identified in TP53-mutant samples derived from patients with poor outcomes or VAF ≥ 75%. TP53 mutations were adversely prognostic among patients with DLBCL assigned to specific LymphGen subtypes (EZB, MCD), malignant B-cell states (S1), and ecotypes (LE4, LE7, LE8), whereas outcomes were similar to wild-type disease within other molecular subtypes. In re-examination of the Phoenix trial data, addition of ibrutinib to R-CHOP improved PFS in patients with TP53-mutant DLBCL and abrogated the deleterious impact of high VAF, irrespective of patients' age. CONCLUSION: The poor prognosis of TP53-mutant DLBCL is dependent on intrinsic features, such as VAF, and modulated by co-occurring genomic lesions or lymphoma cell-intrinsic or microenvironmental expression patterns.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Uppal M, Bhinder B, Marderstein AR, et al. Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2026. PMID: 42054619. doi:10.1200/JCO-25-01928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。